Author: admin

DelveInsight’s “Multiple Sclerosis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Multiple Sclerosis pipeline landscape. It covers the Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Multiple Sclerosis Pipeline @ https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight

Key Takeaways from the Multiple Sclerosis Pipeline Report

• On May 19, 2026- Novartis Pharmaceuticals initiated a phase IV study in which breastfeeding mothers treated with ofatumumab and their babies are taking part for up to 1 year. The study consists of a Core Part and a Safety Follow-up Part. The Core Part includes a Screening period and a Sampling period. During the Screening period (up to 4 weeks), the study doctor will assess if mothers can join the study. The Sampling period, during which milk samples and a blood sample will be collected, will last for up to 12 weeks. The Safety Follow-up Part will last for about 9 months, to follow up on health and safety of mothers and their babies.
• On May 15, 2026- Sanofi conducted a phase 3 study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.
• DelveInsight’s Multiple Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Sclerosis treatment.
• The leading Multiple Sclerosis Companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse and others.
• Promising Multiple Sclerosis Therapies such as 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Multiple Sclerosis Treatment Drugs

The Multiple Sclerosis Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Multiple Sclerosis Pipeline Report also highlights the unmet needs with respect to the Multiple Sclerosis.

Multiple Sclerosis Overview

Multiple Sclerosis is the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. MS attacks the axons of the central nervous system, which are protected by myelin, commonly known as white matter. Relapsing–remitting MS: the most common form, affecting about 85% of MS patients. It is marked by flare-ups (relapses or exacerbations) of symptoms followed by periods of remission, when symptoms improve or disappear.

Multiple Sclerosis Emerging Drugs Profile

• IMU-838: Immunic Therapeutics

Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties.

• BIIB091: Biogen

BIIB091 selectively inhibits Burton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)). Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple sclerosis.

• IMCY-0141: ImCyse

IMCY-0141 is the Company’s second clinical-stage compound. This Imotope is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of Multiple Sclerosis by stopping the body’s immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of multiple sclerosis.

• CC-97540: Bristol-Myers Squibb

CC-97540 is an investigational drug developed by Bristol-Myers Squibb, designed as a selective, orally bioavailable tyrosine kinase 2 (TYK2) inhibitor. TYK2 is a member of the Janus kinase (JAK) family involved in the signaling pathways of several pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and type I interferons, which are implicated in autoimmune and inflammatory diseases. By selectively inhibiting TYK2 without significantly affecting other JAK isoforms, CC-97540 aims to reduce inflammation with potentially fewer side effects compared to broader JAK inhibitors. It is being evaluated for use in conditions such as psoriasis and systemic lupus erythematosus. Currently, the drug is in Phase I stage of its clinical trial for the treatment of multiple sclerosis.

Explore groundbreaking therapies and clinical trials in the Multiple Sclerosis Pipeline @ New Multiple Sclerosis Treatment Drugs

The Multiple Sclerosis Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment.
• Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market

Multiple Sclerosis Companies

Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse and others.

The Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Multiple Sclerosis Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Multiple Sclerosis Market Drivers and Barriers

Scope of the Multiple Sclerosis Pipeline Report

• Coverage- Global
• Multiple Sclerosis Companies- Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse and others.
• Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others.
• Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Multiple Sclerosis Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Multiple sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Multiple sclerosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. IMU-838: Immunic Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. BIIB091: Biogen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NeuroVax: Immune Response BioPharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Multiple sclerosis Key Companies
21. Multiple sclerosis Key Products
22. Multiple sclerosis- Unmet Needs
23. Multiple sclerosis- Market Drivers and Barriers
24. Multiple sclerosis- Future Perspectives and Conclusion
25. Multiple sclerosis Analyst Views
26. Multiple sclerosis Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Sclerosis Treatment Pipeline Witnesses Strong Innovation with 75+ Companies Advancing Novel Therapeutics | DelveInsight

DelveInsight’s “Graves’ Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Graves’ Disease, historical and forecasted epidemiology as well as the Graves’ Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Explore Graves’ Disease Market Trends, treatment landscapes, and emerging therapies shaping the future @ https://www.delveinsight.com/sample-request/graves-disease-market

Key Takeaways from the Graves’ Disease Market Report

• On May 26, 2026, Amgen initiated a clinical trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial (NCT06401044).
• On May 22, 2026- Viridian Therapeutics Inc. announced a study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), controlled study that will include participants with TED of any duration. The key objectives of this study are to determine if VRDN-003 is safe and tolerable when administered as a series of subcutaneous (SC) injections every 4 weeks or every 8 weeks in participants with TED.
• On May 22, 2026- Sanofi conducted a Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves’ disease, with and without Graves’ orbitopathy, aged 18 years or older.
• On May 22, 2026- Immunovant Sciences GmbH initiated a Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves’ disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
• Among the 7MM, the US accounted for approximately 48%, EU4 and the UK for 46%, and Japan for 6% of the total prevalent cases of Graves’ disease in 2023.
• As per the DelveInsight estimates, it has been found that there were approximately 3,720,200 diagnosed prevalent cases of Graves’ disease in the 7MM in 2023.
• In 2023, the manifestation of Graves’ disease in the US showed that Graves’ Ophthalmopathy captured the highest number of cases, i.e., approximately 584,400 cases.
• In 2023, the gender-specific diagnosed prevalent cases of Graves’ disease in Japan were approximately 80,450 cases for males and approximately 321,800 cases for females.
• The leading Graves’ Disease Companies such as Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, Argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, ACELYRIN and others.
• Promising Graves’ Disease Therapies such as linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.

Discover which therapies are expected to grab the Graves’ Disease Market Share @ Graves’ Disease Treatment Market

Graves’ Disease Overview

Graves’ disease is an autoimmune disorder and the most common cause of hyperthyroidism, characterized by the overproduction of thyroid hormones due to the presence of thyroid-stimulating immunoglobulins that activate the thyroid-stimulating hormone (TSH) receptor. This excessive hormone secretion leads to a hypermetabolic state, resulting in symptoms such as weight loss, heat intolerance, palpitations, anxiety, tremors, and fatigue, along with a diffusely enlarged thyroid gland (goiter).

Graves’ Disease Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of Graves’ Disease
• Total Diagnosed Prevalent Cases of Graves’ Disease
• Gender-specific Cases of Graves’ Disease
• Graves’ Disease Cases by Manifestations

Download the report to understand which factors are driving Graves’ Disease epidemiology trends @ Graves’ Disease Prevalence

Graves’ Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graves’ Disease market or expected to get launched during the study period. The analysis covers Graves’ Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Graves’ Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Graves’ Disease Therapies and Companies

• Sling Therapeutics, Inc.: linsitinib

• Immunovant Sciences GmbH: Batoclimab

• Amgen: Teprotumumab

• Viridian Therapeutics Inc.:- VRDN-001 10 mg/kg

• Hoffmann-La Roche: Satralizumab

Graves’ Disease Market Outlook

There are three main treatments for Graves’ disease: ATD medications, thyroidectomy, and radioactive iodine therapy. ATD medications prevent the biosynthesis of the thyroid hormone by blocking iodide, the salted or reduced form of iodine, from interacting with thyroglobulin, thus diminishing the amount of hormone produced. Methimazole is the most widely used ATD medication, with a long half-life and low side effects. Another is carbimazole has been approved in European countries but is not approved in the United States. It is an inactive drug that is metabolized in the blood into the active methimazole thus it is less potent. And the last is propylthiouracil, which is the least potent of the available antithyroid medications. Approved in the United States and Europe, propylthiouracil is the initial treatment choice during the first trimester of pregnancy because of the low placental transfer. Propylthiouracil was, for many years, the first-choice ATD in both the USA and South America. But now the American Thyroid Association (ATA) recommends Methimazole over Propylthiouracil. Methimazole is used in most European countries and Japan, whereas carbimazole is mainly used in the UK.

Marketed Graves’ disease Drugs

• TEPEZZA (Teprotumumab-Trbw): Amgen (Horizon Therapeutics)

Teprotumumab, an insulin-like Growth Factor-1 receptor (IGF-1R) inhibitor, is a fully human IgG1 monoclonal antibody produced in Chinese hamster (CHO-DG44) cells with a molecular weight of approximately 148 KD. In January 2020, the US FDA approved TEPEZZA for the treatment of TED after an accelerated Priority Review. And recently, in September 2024, the drug was approved by Japan’s Ministry of Health, Labour, and Welfare (MHLW) for the treatment of active Graves’ orbitopathy. Additionally, in April 2024, Amgen announced its plans to submit a Marketing Authorization Application (MAA) for teprotumumab to the European Medicines Agency (EMA) in the near future. TEPEZZA is currently under investigation in Phase III clinical trials for patients with moderate-to-severe active Graves’ orbitopathy as well as those with chronic TED characterized by a low Clinical Activity Score (CAS). Additionally, Amgen is exploring its potential for subcutaneous administration.

Get In-Depth Knowledge on Acute on Graves’ disease Market Trends and Forecasts with DelveInsight @ Graves’ disease Market Drivers and Barriers

Emerging Graves’ disease Drugs

• IMVT-1401 (batoclimab, RVT-1401): Immunovant, Samsung Biologics, HanAll Biopharma, and Roivant Sciences

Immunovant’s first investigational product, batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal FcRn. In nonclinical studies and clinical trials, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases, and, as a result, this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered SC injection. Currently, batoclimab is being developed as a low-volume SC injection for the treatment of a variety of IgG-mediated autoimmune disorders, including myasthenia gravis, TED, chronic inflammatory demyelinating polyneuropathy, and Graves’ disease. The drug is currently in Phase III developmental stage. Recently, in September 2024, Immunovant received Investigational New Drug (IND) clearance from the US FDA for IMVT-1402 in Graves’ disease patients who remain hyperthyroid despite treatment with antithyroid drugs. Furthermore, Immunovant plans to initiate clinical trials of IMVT-1402 in a total of ten indications by March 2026.

• VRDN-001 (veligrotug): Viridian Therapeutics

Viridian’s lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting Insulin-like Growth Factor-1 Receptor (IGF-1R), a clinically and commercially validated target for the treatment of Graves’ ophthalmopathy. In preclinical studies, VRDN-001 had shown to be a full antagonist of IGF-1R, with complete receptor blockade than other anti-IGF-1R antibodies, including the only approved Graves’ Ophthalmopathy therapy. Currently, the drug is currently being evaluated in various Phase III trials for the treatment of Graves’ ophthalmopathy. According to a corporate presentation published in November 2024, the potential PDUFA date and launch of veligrotug are expected in 2H 2026.

Scope of the Graves’ Disease Market Report

• Coverage: 7MM

• Study Period: 2020-2034

• Graves’ Disease Companies- Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, Argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, ACELYRIN and others.

• Graves’ Disease Therapies- linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.

• Graves’ Disease Therapeutic Assessment: Graves’ Disease current marketed and Graves’ Disease emerging therapies

• Graves’ Disease Market Dynamics: Graves’ Disease market drivers and Graves’ Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Graves’ Disease Unmet Needs, KOL’s views, Analyst’s views, Graves’ Disease Market Access and Reimbursement

Discover more about Graves’ Disease Drugs in development @ Graves’ Disease Ongoing Clinical Trials

Table of Contents

1. Graves’ Disease Market Report Introduction

2. Executive Summary for Graves’ Disease

3. SWOT analysis of Graves’ Disease

4. Graves’ Disease Patient Share (%) Overview at a Glance

5. Graves’ Disease Market Overview at a Glance

6. Graves’ Disease Disease Background and Overview

7. Graves’ Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Graves’ Disease

9. Graves’ Disease Current Treatment and Medical Practices

10. Graves’ Disease Unmet Needs

11. Graves’ Disease Emerging Therapies

12. Graves’ Disease Market Outlook

13. Country-Wise Graves’ Disease Market Analysis (2020-2034)

14. Graves’ Disease Market Access and Reimbursement of Therapies

15. Graves’ Disease Market Drivers

16. Graves’ Disease Market Barriers

17. Graves’ Disease Appendix

18. Graves’ Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/graves-disease-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graves’ Disease Therapeutics Market Size (7MM) was ~USD 4,400 million in 2023 and is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “MASH Treatment Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of MASH, historical and forecasted epidemiology, as well as the MASH market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the MASH Market Share @ https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market

Key Takeaways from the MASH Market Report

• According to DelveInsight’s estimates, there were more than ~200 million prevalent cases of MASLD (formerly known as NAFLD) in the 7MM in 2025, including ~30 million prevalent cases of MASH. Of the total MASH cases, ~8 million were diagnosed in the 7MM.
• Among the 7MM, the US had the highest number of diagnosed prevalent MASH cases, with ~5 million cases in 2025, a figure projected to increase by 2036.
• In 2025, EU4 and the UK accounted for ~3 million diagnosed prevalent cases of MASH, with Germany having the highest at ~795 thousand cases, followed by Italy with ~630 thousand cases. In contrast, Spain had the least, with ~350 thousand cases.
• In 2025, the UK had ~580 thousand diagnosed prevalent cases of MASH.
• In 2025, Japan recorded ~800 thousand diagnosed prevalent cases of MASH, a number expected to rise by 2036.
• The leading MASH Companies such as Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Inc., Akero Therapeutics, Inc., 89bio, Inc., Boehringer Ingelheim/Zealand Pharma, Galectin Therapeutics Inc., Lipocine Inc, Viking Therapeutics, Inc., Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Inc., Merck & Co./Hanmi Pharmaceutical, Hepagene (Shanghai) Co., Ltd., Hepion Pharmaceuticals, Inc., Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences Inc., Ionis Pharmaceuticals, and Corcept Therapeutics and others.
• Promising MASH Pipeline Therapies such as TVB-2640, Survodutide, Miricorilant (Cohort B), Efimosfermin, Pegozafermin, DD01, ALG-055009, and others.

Stay ahead in the MASH Therapeutics Market with DelveInsight’s Strategic Report @ MASH Treatment Market

MASH Epidemiology Segmentation in the 7MM

• Total MASH Prevalent Cases
• Total Diagnosed Prevalent Cases
• MASH Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving MASH Epidemiology trends @ MASH Prevalence

MASH Marketed Drugs

• REZDIFFRA (resmetirom): Madrigal Pharmaceuticals

REZDIFFRA (resmetirom), a Thyroid Hormone Receptor-beta (THR-ß) agonist, is approved for treating adults with noncirrhotic MASH and moderate to advanced liver fibrosis (F2-F3), in conjunction with diet and exercise. It received accelerated approval due to improvements in MASH and fibrosis. In March 2024, the US FDA approved REZDIFFRA for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3).

MASH Emerging Drugs

• Efruxifermin (EFX): Akero Therapeutics

Efruxifermin (EFX), Akero Therapeutics’ leading candidate for MASH, is an engineered Fc-FGF21 fusion protein mimicking the biological activity of native FGF21. EFX has shown promise in reducing liver fat, inflammation, and fibrosis, while enhancing insulin sensitivity and lipid metabolism. It offers once-weekly dosing and a favorable tolerability profile in clinical trials. Currently, EFX is being evaluated in three Phase III studies, with encouraging results from Phase II trials showing its potential to reverse fibrosis and improve liver function. The Phase III SYNCHRONY study is expected to provide results in 2026.

• VK2809 (TRß Agonist): Viking Therapeutics

VK2809 is an orally available, liver-targeted agonist of the Thyroid Hormone Beta Receptor (TRß), designed to specifically modulate lipid metabolism. By selectively activating TRß in liver tissue, VK2809 aims to improve cholesterol and lipoprotein levels through the upregulation of genes involved in lipid clearance. The compound has shown significant therapeutic potential in lipid disorders, meeting both primary and secondary endpoints in the Phase IIb VOYAGE study for patients with NASH/MASH and fibrosis, as well as in a Phase IIa study for patients with elevated LDL-C and MASLD.

• Efimosfermin alfa (formerly BOS-580): Boston Pharmaceuticals

Efimosfermin alfa (BOS-580), developed by Boston Pharmaceuticals, is a long-acting variant of FGF21 designed to regulate metabolic pathways, reducing liver fat, inflammation, and fibrosis in MASH patients. Manufactured in mammalian cells for human-like glycosylation, it is administered as a once-monthly subcutaneous injection. BOS-580 is currently undergoing Phase II trials for MASH treatment. In September 2020, Boston Pharmaceuticals licensed the genetically engineered FGF21 variant from Novartis, positioning it as a potential best-in-class treatment for MASH.

To learn more about MASH Treatment guidelines, visit @ MASH Clinical Trials Assessment

MASH Companies

Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Inc., Akero Therapeutics, Inc., 89bio, Inc., Boehringer Ingelheim/Zealand Pharma, Galectin Therapeutics Inc., Lipocine Inc, Viking Therapeutics, Inc., Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Inc., Merck & Co./Hanmi Pharmaceutical, Hepagene (Shanghai) Co., Ltd., Hepion Pharmaceuticals, Inc., Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences Inc., Ionis Pharmaceuticals, and Corcept Therapeutics and others.

MASH Drugs Market Insights

Efruxifermin (EFX) is an investigational Fc-FGF21 fusion protein developed by Akero Therapeutics for the treatment of MASH. Designed to mimic the biological activity of FGF21, EFX aims to address key drivers of MASH by reducing liver fat and inflammation, reversing fibrosis, and improving insulin sensitivity and lipid metabolism. In a 96-week Phase IIb study, 39% of patients with compensated cirrhosis due to MASH experienced a reversal of cirrhosis without worsening of the disease, compared to 15% in the placebo group. These promising results have led to the initiation of the Phase III SYNCHRONY clinical program, which includes trials evaluating EFX in patients with pre-cirrhotic MASH (F2-F3 fibrosis) and those with compensated cirrhosis (F4) due to MASH.

MASH Treatment Market

The MASH treatment landscape is rapidly evolving, particularly with the USFDA’s accelerated approval of Madrigal’s REZDIFFRA, now considered a key therapy for patients with moderate to advanced liver fibrosis. This selective thyroid hormone receptor-beta agonist has shifted the approach from invasive liver biopsies to non-invasive diagnostic methods, improving patient access to treatment. The landscape is further shaped by a diverse pipeline of therapies targeting various mechanisms, such as FXR agonists, PPAR modulators, and GLP-1 receptor agonists, with clinical trials exploring combination therapies to address the complex nature of the disease. As researchers focus on personalized medicine and better patient stratification, the priority remains refining treatment strategies while navigating challenges in trial recruitment and regulatory requirements. The combination of emerging therapies and existing lifestyle interventions continues to influence clinical practice in managing MASH/NASH.

Learn more about the FDA-approved drugs for MASH @ Drugs for MASH Treatment

Scope of the MASH Market Report

• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• MASH Companies- Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Inc., Akero Therapeutics, Inc., 89bio, Inc., Boehringer Ingelheim/Zealand Pharma, Galectin Therapeutics Inc., Lipocine Inc, Viking Therapeutics, Inc., Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Inc., Merck & Co./Hanmi Pharmaceutical, Hepagene (Shanghai) Co., Ltd., Hepion Pharmaceuticals, Inc., Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences Inc., Ionis Pharmaceuticals, and Corcept Therapeutics and others.
• MASH Pipeline Therapies- TVB-2640, Survodutide, Miricorilant (Cohort B), Efimosfermin, Pegozafermin, DD01, ALG-055009, and others.
• MASH Market Dynamics: MASH Market Drivers and Barriers
• MASH Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents

1. Key Insights
2. MASH Market Report Introduction
3. MASH Market Overview at a Glance
4. Methodology of Epidemiology and Market
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. MASH Epidemiology and Patient Population
9. Patient Journey
10. MASH Marketed Drugs
11. MASH Emerging Drugs
12. MASH – 7MM Market Analysis
13. Key Opinion Leaders’ Views
14. MASH Unmet Needs
15. MASH SWOT Analysis
16. MASH Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metabolic-dysfunction-associated-steatohepatitis-mash-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MASH Therapeutics Market Size (7MM) was ~USD 3 Billion in 2025 and it is projected to grow at a significant CAGR by 2036, estimates Delveinsight

DelveInsight’s, “Osteoarthritis Pipeline Insights 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Osteoarthritis Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight

Key Takeaways from the Osteoarthritis Pipeline Report

• On May 22, 2026, Eli Lilly and Company initiated a phase 3 study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
• On May 06, 2026, Kolon TissueGene Inc. announced a phase 3 study to determine the efficacy and safety of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy.
• DelveInsight’s Osteoarthritis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Osteoarthritis treatment.
• The leading Osteoarthritis Companies such as Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others.
• Promising Osteoarthritis Pipeline Therapies such as MK0663, Etoricoxib, Diacerein, Celecoxib, RTX-GRT7039, Naproxcinod, Naproxen, LY3857210, LY3556050, LY3016859, Ibuprofen, Voltaren® Gel, Gevokizumab and others.

Access DelveInsight’s in-depth Osteoarthritis Pipeline Analysis for a closer look at promising breakthroughs @ Osteoarthritis Clinical Trials and Studies

Osteoarthritis Overview

Osteoarthritis is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work. Osteoarthritis is the most common type of arthritis, characterized by the gradual breakdown of cartilage in joints, leading to pain, stiffness, and swelling. Symptoms often include joint pain that worsens with activity and improves with rest, stiffness lasting less than 30 minutes after inactivity, and a sensation of joint instability or looseness. Affected joints may also produce a grinding or creaking sound during movement, and swelling can occur, particularly after prolonged use.

Osteoarthritis Emerging Drugs Profile

• Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. The drug is currently in Phase III stage of clinical trial evaluation to treat the patients suffering from osteoarthritis.

• EP-104IAR: Eupraxia Pharmaceuticals

Eupraxia’s lead product candidate, EP-104IAR, is designed to meet the significant unmet medical need and market demand for long-lasting disease relief in multiple indications benefitting from highly localized and longer delivery of corticosteroids. The lead indication is for pain relief in knee OA. EP-104IAR is designed to prolong the duration of pain relief with fewer unwanted side effects. It encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane, part of Eupraxia’s patented technology platform. Injected into the knee, EP-104IAR is designed to diffuse the corticosteroid slowly into the knee joint providing local therapeutic concentrations for up to six months. This has the potential dual advantage of providing longer duration of pain relief with fewer systemic side effects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of OA.

• DFV890: Novartis

DFV890 is a small molecule, NOD-like receptor protein 3 (NLRP3) antagonist being developed by Novartis for the treatment of various inflammatory conditions. It is currently being evaluated in several phase I and II clinical trials, including studies in myeloid diseases, knee osteoarthritis, COVID-19, and cardiovascular disease. DFV890 works by inhibiting the NLRP3 protein, which plays a key role in the activation of the inflammatory response. Currently, the drug is in Phase II stage of its clinical trial for the treatment of OA.

• 4P004: 4P-Pharma

4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties. 4P004 was developed in collaboration with the team of Prof. Francis Berenbaum and SATT Lutech. 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech. Currently, the drug is in Phase II stage of its clinical trial for the treatment of OA.

• GNSC 001: Genascence

GNSC-001 is a genetic medicine – a recombinant adeno-associated viral vector expressing an optimized form of IL-1Ra, a naturally occurring protein that blocks interleukin-1 (IL-1) signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, as well as cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single injection into the affected joint. Currently, the drug is in Phase I stage of its clinical trial for the treatment of OA.

The Osteoarthritis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Osteoarthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoarthritis Treatment.
• Osteoarthritis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoarthritis market.

Get a detailed analysis of the latest innovations in the Osteoarthritis pipeline @ Osteoarthritis Unmet Needs

Osteoarthritis Companies

Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others.

Osteoarthritis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Osteoarthritis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Osteoarthritis Therapies @ Osteoarthritis Market Drivers and Barriers, and Future Perspectives

Scope of the Osteoarthritis Pipeline Report

• Coverage- Global
• Osteoarthritis Companies- Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others.
• Osteoarthritis Pipeline Therapies- MK0663, Etoricoxib, Diacerein, Celecoxib, RTX-GRT7039, Naproxcinod, Naproxen, LY3857210, LY3556050, LY3016859, Ibuprofen, Voltaren® Gel, Gevokizumab and others.
• Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Osteoarthritis drug development? @ Osteoarthritis Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Osteoarthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Osteoarthritis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Lorecivivint: Biosplice Therapeutics
9. Mid Stage Products (Phase II)
10. EP-104IAR: Eupraxia Pharmaceuticals
11. Early Stage Products (Phase I)
12. GNSC 001: Genascence
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Osteoarthritis Key Companies
17. Osteoarthritis Key Products
18. Osteoarthritis- Unmet Needs
19. Osteoarthritis- Market Drivers and Barriers
20. Osteoarthritis- Future Perspectives and Conclusion
21. Osteoarthritis Analyst Views
22. Osteoarthritis Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Osteoarthritis Pipeline Continues Rapid Expansion with 100+ Companies Advancing Musculoskeletal Programs | DelveInsight

DelveInsight’s “Cushing Syndrome Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cushing Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Cushing Syndrome Pipeline? @ https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight

Key Takeaways from the Cushing Syndrome Pipeline Report

• On May 12, 2026, Sparrow Pharmaceuticals initiated a clinical trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol. CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben.
• DelveInsight’s Cushing Syndrome Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Cushing Syndrome treatment.
• The leading Cushing Syndrome Companies such as Stero Therapeutics, Sparrow Pharmaceuticals and others.
• Promising Cushing Syndrome Therapies such as SOM230 LAR 30 mg, Pasireotide LAR, Osilodrostat, SPI-62, Mifepristone, Levoketoconazole, mifepristone, CORT125134 and others.

Want to know which companies are leading innovation in Cushing Syndrome? @ Cushing Syndrome Clinical Trials Assessment

The Cushing Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Cushing Syndrome Pipeline Report also highlights the unmet needs with respect to the Cushing Syndrome.

Cushing Syndrome Overview

Cushing’s syndrome arises from prolonged exposure to elevated levels of circulating glucocorticoids, with Cushing’s disease, pituitary-dependent hypercortisolism, being the most common cause of endogenous cases. It is characterized by a wide range of symptoms, with common manifestations including decreased libido, obesity or weight gain, plethora (reddish complexion), rounded face, menstrual changes, hirsutism, hypertension, easy bruising (ecchymoses), lethargy, depression, proximal muscle weakness, and skin changes such as striae. Less common symptoms may involve EKG abnormalities or atherosclerosis, dorsal fat pad, edema, abnormal glucose tolerance, osteopenia or fractures, headaches, backaches, recurrent infections, abdominal pain, acne, and female-pattern baldness.

Cushing Syndrome Emerging Drugs

• ST-002: Stero Therapeutics

ST-002 is specifically designed to address the hyperglycemia and non-alcoholic steatohepatitis (NASH) associated with Cushing’s syndrome, offering a unique combination of glucocorticoid inhibition, anti-inflammatory, and anti-diabetic effects. Unlike other anti-glucocorticoid drugs, ST-002 suppresses glucocorticoid activity without reducing glucocorticoid levels, thereby avoiding adrenal insufficiency. Its safety profile has been established in over 120 patients using prior oral formulations, and as a new chemical entity (NCE), ST-002 demonstrates improved bioavailability and solubility compared to earlier versions. The U.S. FDA has granted it Orphan Disease Designation, and SteroTherapeutics is advancing its development in collaboration with the NIH under a Cooperative Research and Development Agreement (CRADA). Currently, the drug is in Phase II stage of its clinical trial for Cushing Syndrome.

If you’re tracking ongoing Cushing Syndrome Clinical trials, this press release is a must-read @ Cushing Syndrome Treatment Drugs

The Cushing Syndrome Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Cushing Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cushing Syndrome Treatment.
• Cushing Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cushing Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cushing Syndrome market.

Cushing Syndrome Companies

Stero Therapeutics, Sparrow Pharmaceuticals and others.

Cushing Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Cushing Syndrome Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Cushing Syndrome Pipeline Report covers it all @ Cushing Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Cushing Syndrome Pipeline Report

• Coverage- Global
• Cushing Syndrome Companies- Stero Therapeutics, Sparrow Pharmaceuticals and others.
• Cushing Syndrome Therapies- SOM230 LAR 30 mg, Pasireotide LAR, Osilodrostat, SPI-62, Mifepristone, Levoketoconazole, mifepristone, CORT125134 and others.
• Cushing Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cushing Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Cushing Syndrome Treatment landscape in this detailed analysis @ Cushing Syndrome Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Cushing Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cushing Syndrome– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ST-002: Stero Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cushing Syndrome Key Companies
21. Cushing Syndrome Key Products
22. Cushing Syndrome- Unmet Needs
23. Cushing Syndrome- Market Drivers and Barriers
24. Cushing Syndrome- Future Perspectives and Conclusion
25. Cushing Syndrome Analyst Views
26. Cushing Syndrome Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cushings-syndrome-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cushing Syndrome Clinical Trial Pipeline Expands with Robust Contributions from 4+ Global Biopharma Companies | DelveInsight